{"prompt": "['MK-7902', 'PAGE 35', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'reduction from the global primary efficacy analysis assuming the same hazard ratio used in the', 'sample size and power calculation for the global study. The primary analysis for PFS will be', 'conducted in the Chinese subpopulation when approximately 75 PFS events have been collected.', '4.6.1.2.', 'Overall Survival', 'Analysis of OS for extension is the same to that for the global study if applicable.', 'The nonparametric Kaplan-Meier method will be used to estimate the survival curves. The', 'treatment difference in os will be assessed by the stratified log-rank test (based on the', 'stratification factors defined in Section 6.3.2 in the protocol). A stratified Cox proportional', \"hazard model with Efron's method of tie handling will be used to assess the magnitude of the\", 'treatment difference (ie, the HR). The HR and its 95% CI from the stratified Cox model with a', 'single treatment covariate will be reported. The stratification factors used for randomization', '(Section 6.3.2 in the protocol) will be applied to both the stratified log-rank test and the stratified', 'Cox model. The same stratification factors used in the global study will be used. For the Chinese', 'subgroup analysis, the stratified method will only be used if applicable. The factor of Geography', '(East Asia VS. non-East Asia) will not be included in the stratified analysis for the Chinese', 'subgroup analysis. Participants without documented death at the time of analysis will be', 'censored at the date of last known contact. An analysis using the restricted mean survival time', 'method may be conducted for os to account for the possible nonproportional hazards effect.', 'Consistency in os will be evaluated similarly as that in PFS. The primary analysis for OS will be', 'conducted in the Chinese subpopulation when approximately 75 OS events have been collected.', '4.6.1.3.', 'Objective Response Rate', 'Analysis of ORR or DOR for extension is the same to that for the global study if applicable.', 'The stratified Miettinen and Nurminen method will be used for comparison of ORR between the', 'treatment groups. The difference in ORR and its 95% CI from the stratified Miettinen and', 'Nurminen method with strata weighting by sample size will be provided. The same stratification', 'factors used for randomization (Section 6.3.2 of the study protocol) will be used as stratification', 'factors in the analysis. The same stratification factors used in the global study will be used. For', 'the Chinese subpopulation analysis, the stratified method will only be used if applicable. The', 'factor of Geography (East Asia vs. non-East Asia) will not be included in the stratified analysis', 'for Chinese subgroup analysis.', '4.6.1.4.', 'Duration of Response', 'For subjects who demonstrate CR or PR, DOR is defined as the time from first documented', 'evidence of CR or PR until PD or death due to any cause, whichever occurs first.', 'The nonparametric Kaplan-Meier method will be used to summarize the DOR. The median and', 'range of DOR will be provided.', 'Confidential']['MK-7902', 'PAGE 36', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', '4.6.2.', 'Statistical Methods for Safety Analyses', 'Safety analyses for extension are the same to that for the global study as described in Section 3.6.2.', '4.6.3.', 'Statistical Methods for PRO Analysis', 'PRO Analysis are the same for extension to that for the global study as described in Section 3.6.3.', '4.6.4.', 'Summaries of Baseline Characteristics, Demographics, and Other Analyses', 'They are the same for extension to that for the global study as described in Section 3.6.4.', '4.7. Interim Analysis and Final analysis', 'The primary analysis for PFS will be conducted in the Chinese subpopulation when approximately', '75 PFS events have been collected. OS will also be analyzed.', 'The primary analysis for os will be conducted in the Chinese subpopulation when approximately', '75 os events have been collected.', '4.8. Multiplicity', 'No multiplicity adjustment will be applied to the analysis of China.', '4.9. Sample Size and Power Calculations', 'After the completion of global study enrollment, the extension portion will continue to enroll', 'participants and randomize eligible participants until the sample size for the overall randomized', 'Chinese subpopulation reaches approximately 120. Participants from China enrolled in the', 'extension portion of this study after completion of the global enrollment will not be included in', 'the primary efficacy analysis population for the global study.', 'The extension portion will complete after approximately 75 OS events have been observed', 'between the two arms in the Chinese subpopulation. With 75 os events and a true hazard ratio of', '0.7, the extension portion has ~80% chance to observe a point estimate of os that preserves', '>', 'approximately 50% of the empirical risk reduction from the global analysis in the Chinese', 'subpopulation. With 75 PFS events and a true hazard ratio of 0.7, the extension portion has ~80%', 'chance to observe a point estimate of PFS that preserves > approximately 50% of the empirical', 'risk reduction from the global analysis in the Chinese subpopulation.', 'The above calculations for the consistency evaluation in OS and PFS are based on the same', 'assumptions in the global study for sample size and power evaluation as specified in Section 3.9.', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}